Abstract
Tumor hypoxia is a negative prognostic factor for prostate cancer (PCa) radiation therapy (RT) in part due to radioresistance of hypoxic cells. Inhibition of oxygen consumption is a strategy to increase diffusion of oxygen in tumor tissue, reduce tumor hypoxia and increase radiation response. Metformin, a common anti-diabetic agent, reduces cellular oxygen consumption by inhibiting complex I in the mitochondrial electron transport chain. Using both pre-clinical and clinical studies we tested whether metformin decreased therapeutically relevant hypoxia and improved outcomes following PCa RT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
